State Street SPDR S&P Pharmaceuticals ETF
XPH
79 hedge funds and large institutions have $337M invested in State Street SPDR S&P Pharmaceuticals ETF in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 16 reducing their positions, and 10 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 16
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
9% more capital invested
Capital invested by funds: $308M → $337M (+$28.4M)
1% more funds holding
Funds holding: 78 → 79 (+1)
1.7% less ownership
Funds ownership: 58.97% → 57.27% (-1.7%)
13% less call options, than puts
Call options by funds: $593K | Put options by funds: $679K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$4.35M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$4.09M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.34M |
| 4 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
+$3.14M |
| 5 |
Jane Street
New York
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$17.8M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$12.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.69M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.46M |
| 5 |
Morgan Stanley
New York
|
-$922K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TFA
76
Transamerica Financial Advisors
St. Petersburg,
Florida
| $1K | – | – | – |
|
|
FNBT
77
FineMark National Bank & Trust
Fort Myers,
Florida
| $1K | +$1.42K | +24 | New |
|
78
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $6 | +$6.05K | +102 | New |
|
|
79
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$5.46M | -101,158 | Closed |
|
80
HSBC Holdings
London,
United Kingdom
| – | -$540K | -10,000 | Closed |
|
81
JP Morgan Chase
New York
| – | -$464K | -8,594 | Closed |
|
82
Ameriprise
Minneapolis,
Minnesota
| – | -$388K | -7,188 | Closed |
|
83
Fisher Asset Management
Camas,
Washington
| – | -$370K | -6,850 | Closed |
|
|
DWA
84
Dorsey Wright & Associates
Pasadena,
California
| – | -$343K | -4,564 | Closed |
|
|
PFG
85
Pacific Financial Group
Bellevue,
Washington
| – | -$246K | -4,548 | Closed |
|
|
NPC
86
National Planning Corporation
El Segundo,
California
| – | -$101K | -1,850 | Closed |
|
|
GT
87
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$53K | -1,000 | Closed |
|
|
PMFA
88
Plante Moran Financial Advisors
Southfield,
Michigan
| – | -$3K | -48 | Closed |
|
XPH Hedge Fund Activity: Q1 2015 in Review
79 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2015, worth a combined $337M — up 9.2% from $308M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new XPH positions and 10 closed out — a net gain of 4 holders — while 36 added to existing stakes and 16 trimmed.
The largest buyer was Wells Fargo, adding an estimated $4.35M. The largest seller was Goldman Sachs, cutting an estimated $17.8M.
- 79 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2015, up from 78 in Q4 2014.
- Funds reported $337M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2015, up 9.2% quarter-over-quarter.
- 14 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2015 and 10 closed out, a net change of +4 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2015 was Wells Fargo, an estimated $4.35M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2015 was Goldman Sachs, an estimated $17.8M sold.
Based on aggregated 13F filings for Q1 2015.